ADGM revenueQ2 2026$0
ADGM revenue was $0 in fiscal Q2 2026 (ended Jun 30, 2026), compared with $0 a year earlier. For the full fiscal 2025 it was $0.
Adagio Medical Holdings Inc (ADGM) financials
For the twelve months ended Jun 30, 2026, Adagio Medical Holdings Inc reported $0 of revenue and -$27.14M of net income.
- Revenue, TTM
- $0
- Net income, TTM
- -$27.14M
- Free cash flow, TTM
- -$17.55M
- EPS, diluted, TTM
- -$1.26
- Cash
- $7.74M
- Total debt
- $24.84M
- Market cap
- $57.0M
FY2023FY2025
FY2023FY2025
FY2023FY2025
ADGM revenue and earnings growth
ADGM net incomeQ2 2026-$6.72M
ADGM net income was -$6.72M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$3.95M a year earlier. For the full fiscal 2025 it was -$25.08M.
ADGM EPSQ2 2026-$0.30
ADGM diluted EPS was -$0.30 in fiscal Q2 2026 (ended Jun 30, 2026). For the full fiscal 2025 it was -$1.51.
ADGM free cash flowQ2 2026-$5.27M
ADGM free cash flow was -$5.27M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$4.67M a year earlier. For the full fiscal 2025 it was -$19.39M.
Income statement
| Line item | Dec 31, 2025 | Dec 31, 2023 |
|---|---|---|
| Revenue | $0 | $300.0K |
| Cost of revenue | $684.0K | $1.31M |
| Gross profit | -$684.0K | -$1.01M |
| Research and development | $10.64M | $15.40M |
| Selling, general and admin | $10.57M | $11.54M |
| Operating income | -$21.89M | -$27.94M |
| Interest expense | $2.91M | $1.66M |
| Pre-tax income | -$25.32M | -$36.59M |
| Income tax | $0 | $0 |
| Net income | -$25.08M | -$36.59M |
| EPS, basic | -$1.51 | -$48.16 |
| EPS, diluted | -$1.51 | -$48.16 |
| Diluted shares | 16.6M | - |
Balance sheet
| Line item | Dec 31, 2025 | Dec 31, 2023 |
|---|---|---|
| Cash and equivalents | $17.11M | $1.38M |
| Receivables | - | $71.0K |
| Inventory | $1.67M | $3.32M |
| Current assets | $20.08M | $5.18M |
| Goodwill | $13.97M | $0 |
| Total assets | $43.25M | $6.83M |
| Current liabilities | $8.23M | $47.18M |
| Long-term debt | $21.04M | - |
| Total debt | $21.04M | $38.27M |
| Total liabilities | $30.85M | $47.38M |
| Shareholders' equity | $12.40M | -$132.02M |
Cash flow
| Line item | Dec 31, 2025 | Dec 31, 2023 |
|---|---|---|
| Operating cash flow | -$19.01M | -$25.65M |
| Capital expenditures | $374.0K | $333.0K |
| Free cash flow | -$19.39M | -$25.98M |
| Investing cash flow | -$374.0K | -$340.0K |
| Financing cash flow | $16.13M | $21.88M |
| Stock-based compensation | $1.48M | $442.0K |
| Depreciation and amortization | $970.0K | $532.0K |
Key ratios
Income statement
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | - | $254.0K | $26.0K | $78.0K | $41.0K |
| Cost of revenue | - | - | $58.0K | $31.0K | $342.0K | $253.0K | - | $682.0K | $542.0K | $334.0K | $253.0K |
| Gross profit | - | - | -$58.0K | -$31.0K | -$342.0K | -$253.0K | - | -$428.0K | -$516.0K | -$256.0K | -$212.0K |
| Research and development | $2.45M | $2.74M | $2.23M | $2.77M | $1.97M | $3.66M | - | $2.87M | $3.47M | $1.77M | $4.42M |
| Selling, general and admin | $2.48M | $2.46M | $1.68M | $2.92M | $2.40M | $3.48M | - | $3.37M | $4.83M | $3.30M | $4.45M |
| Operating income | -$4.93M | -$5.20M | -$3.97M | -$5.72M | -$4.72M | -$7.40M | - | -$6.66M | -$8.81M | -$5.33M | -$9.08M |
| Interest expense | $805.0K | $778.0K | $775.0K | $749.0K | $720.0K | $662.0K | - | $760.0K | $754.0K | $577.0K | $485.0K |
| Net income | -$6.72M | -$7.00M | -$3.31M | -$10.12M | -$3.95M | -$7.71M | -$8.23M | -$5.73M | -$8.02M | -$8.62M | -$10.76M |
| EPS, basic | -$0.30 | -$0.31 | -$0.09 | -$0.66 | -$0.26 | -$0.50 | -$8.34 | -$7.35 | -$10.28 | - | -$14.15 |
| EPS, diluted | -$0.30 | -$0.31 | $0.01 | -$0.66 | -$0.35 | -$0.51 | - | -$7.35 | -$10.28 | - | -$14.15 |
| Diluted shares | 22.2M | 22.2M | - | 15.4M | 15.4M | 15.4M | - | 779,908 | - | - | - |
Balance sheet
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $7.74M | $12.91M | $17.11M | $4.67M | $8.20M | $12.96M | $28.26M | $2.04M | $4.08M | $1.38M | $1.98M |
| Receivables | - | - | - | - | - | $1.0K | $90.0K | - | - | $71.0K | - |
| Inventory | $1.99M | $1.60M | $1.67M | $1.55M | $1.84M | $2.31M | $4.14M | - | - | $3.32M | - |
| Current assets | $10.69M | $15.86M | $20.08M | $8.14M | $12.23M | $17.37M | $35.03M | - | - | $5.18M | - |
| Goodwill | $13.97M | $13.97M | $13.97M | $13.97M | $13.97M | $13.97M | $44.29M | - | - | $0 | - |
| Total assets | $33.88M | $39.31M | $43.25M | $31.55M | $35.88M | $41.34M | $107.20M | - | - | $6.83M | - |
| Current liabilities | $7.56M | $8.57M | $8.23M | $9.70M | $4.88M | $6.01M | $7.92M | - | - | $47.18M | - |
| Long-term debt | $24.84M | $22.87M | $21.04M | $21.19M | $16.95M | $17.65M | $13.75M | - | - | - | - |
| Total debt | $24.84M | $22.87M | $21.04M | $21.19M | $16.95M | $17.65M | $13.75M | - | - | $38.27M | - |
| Total liabilities | $34.30M | $33.58M | $30.85M | $32.86M | $27.21M | $28.94M | $30.64M | $5.0K | - | $47.38M | - |
| Shareholders' equity | -$415.0K | $5.72M | $12.40M | -$1.31M | $8.67M | $12.40M | $76.56M | -$140.51M | -$139.22M | -$132.02M | -$123.51M |
Cash flow
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$5.26M | -$4.13M | -$4.14M | -$3.01M | -$4.66M | -$7.21M | - | -$6.95M | -$6.74M | -$7.09M | - |
| Capital expenditures | $6.0K | $2.0K | -$491.0K | $520.0K | $10.0K | $335.0K | - | $175.0K | $162.0K | $20.0K | - |
| Free cash flow | -$5.27M | -$4.13M | -$4.63M | -$3.53M | -$4.67M | -$7.55M | - | -$7.12M | -$6.90M | -$7.11M | - |
| Investing cash flow | -$6.0K | -$2.0K | $491.0K | -$520.0K | -$10.0K | -$335.0K | - | -$175.0K | -$162.0K | -$20.0K | - |
| Financing cash flow | - | - | - | - | - | - | - | $5.07M | $9.57M | $6.58M | - |
| Stock-based compensation | $479.0K | $389.0K | $890.0K | $137.0K | $234.0K | $218.0K | - | $111.0K | $110.0K | $113.0K | - |
| Depreciation and amortization | $201.0K | $210.0K | $237.0K | $191.0K | $271.0K | $271.0K | - | $257.0K | $330.0K | $133.0K | - |
Key ratios
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth, YoY | - | - | - | - | -100.0% | -100.0% | - | - | - | - | - |
| Gross margin | - | - | - | - | - | - | - | -168.5% | -1984.6% | -328.2% | -517.1% |
| Operating margin | - | - | - | - | - | - | - | -2621.7% | -33903.8% | -6837.2% | -22148.8% |
| Net margin | - | - | - | - | - | - | - | -2257.5% | -30838.5% | -11052.6% | -26246.3% |
| Free cash flow margin | - | - | - | - | - | - | - | -2803.1% | -26542.3% | -9116.7% | - |
| Current ratio | 1.41 | 1.85 | 2.44 | 0.84 | 2.50 | 2.89 | 4.42 | - | - | 0.11 | - |
| Debt to equity | - | 4.00 | 1.70 | - | 1.96 | 1.42 | 0.18 | - | - | - | - |
Source: XBRL data Adagio Medical Holdings Inc files with the SEC, latest filing dated Aug 11, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures are as filed. The filings show no stock split in these periods.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
ADGM peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| ADGM | $0 | - | -$27.14M | - | $57.0M |
| SYK | $26.30B | +7.9% | $3.62B | 13.8% | $124.00B |
| MMM | $25.25B | +1.7% | $3.54B | 14.0% | $97.47B |
| BSX | $21.07B | +8.9% | $3.50B | 16.6% | $63.81B |
| BDX | $23.25B | +17.4% | $941.00M | 4.0% | $58.63B |
| MDLN | $30.68B | - | $683.00M | 2.2% | $53.55B |
| RMD | $5.73B | +9.0% | $1.59B | 27.8% | $33.16B |
| DXCM | $5.10B | +13.0% | $991.00M | 19.4% | $30.24B |
| WST | $3.40B | +12.6% | $638.90M | 18.8% | $28.78B |
ADGM FAQ
7 questionsWhat is ADGM revenue?
Adagio Medical Holdings Inc (ADGM) reported $0 of revenue for the twelve months ended Jun 30, 2026. Revenue for fiscal 2025 was $0.Is ADGM profitable?
No. Adagio Medical Holdings Inc reported a net loss of $27.14M for the twelve months ended Jun 30, 2026.How much cash and debt does ADGM have?
Adagio Medical Holdings Inc reported $7.74M in cash and cash equivalents and $24.84M of debt on its most recent balance sheet in SEC filings.What is ADGM free cash flow?
Adagio Medical Holdings Inc generated -$17.55M of free cash flow for the twelve months ended Jun 30, 2026, which is operating cash flow of -$16.53M less capital expenditures.What is ADGM earnings per share?
Diluted earnings per share were -$1.26 for the twelve months ended Jun 30, 2026, from SEC filings, restated for any stock split those filings show.When did ADGM last report financial results?
The latest statements here come from Adagio Medical Holdings Inc's 10-Q filed on Aug 11, 2026, covering the period ended Jun 30, 2026.Where does this ADGM financial data come from?
Quantisnow builds these statements from the structured XBRL data Adagio Medical Holdings Inc files with the SEC. It is provided for information only and is not investment advice.